Drug Manufacture FDA Approves Lundbeck’s Rexulti for Alzheimer’s AgitationBy MohamedMis2July 25, 2023 The FDA’s recent approval of Lundbeck-Otsuka’s Rexulti marks a significant milestone in Alzheimer’s disease treatment[1]. The medication has been specifically…
Drug Manufacture FDA Approves Rexulti for Alzheimer’s AgitationBy MohamedMis2July 21, 2023 Alzheimer’s disease, a distressing and degenerative condition, can lead to troubling symptoms like agitation. However, there is now a glimmer…
Asset Management AIM ImmunoTech reported a GAAP EPS of -$0.40By MohamedMis2July 17, 2023 AIM ImmunoTech recently reported disappointing financial results, with a GAAP EPS of -$0.40 and revenue of $0.14M [1]. This signifies…
